Atea Pharmaceuticals Confirms Receipt of Unsolicited Proposal from Tang Capital Partners’ Affiliate, Concentra Biosciences
May 23, 2023 16:05 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, May 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”) confirmed that it has received an unsolicited proposal from Tang Capital, LP on behalf of Concentra...
Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
May 08, 2023 16:05 ET
|
Atea Pharmaceuticals, Inc.
Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint Phase 2 trial evaluating...
Atea Pharmaceuticals to Host First Quarter 2023 Financial Results Conference Call on May 8, 2023
May 01, 2023 16:05 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
Atea Pharmaceuticals Announces U.S. FDA Fast Track Designation Granted to Bemnifosbuvir, an Investigational Oral Antiviral, for the Treatment of COVID-19
April 25, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, April 25, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral...
Atea Announces Presentation of Bemnifosbuvir Data Demonstrating Reduced Hospitalizations for COVID-19 Patients at 2023 European Congress of Clinical Microbiology & Infectious Diseases
April 12, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, April 12, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct...
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C Presented at 2023 International Conference on Antiviral Research
March 14, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
Low risk for drug-drug interactions with bemnifosbuvir based upon results from in vitro metabolism and transporter studies Bemnifosbuvir retains activity against all SARS-CoV-2 variants of concern...
New Data Showcasing Favorable Profile of Bemnifosbuvir for Treatment of COVID-19 and Hepatitis C to be Presented at 2023 International Conference on Antiviral Research
March 08, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, March 08, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral direct...
Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
February 28, 2023 16:05 ET
|
Atea Pharmaceuticals, Inc.
Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; interim analysis expected in 2H23 Phase 2 trial evaluating combination of...
Atea Pharmaceuticals Presents Favorable Drug Interaction Profile of Bemnifosbuvir in Phase 1 Studies at CROI 2023
February 23, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
Results highlight the favorable profile for bemnifosbuvir related to low risk for drug-drug interactions BOSTON, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR)...
Atea Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023
February 21, 2023 07:00 ET
|
Atea Pharmaceuticals, Inc.
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that it will host a live conference call and...